Table 1.
Baseline Demographic, HIV-related and Substance Use Data
| N | 636 |
|
| |
| Length of follow-up (years), median (IQR) | 1.58 (.8, 3.4) |
|
| |
| Neuropathy Cumulative Incidence, n (%) | 261 (41%) |
|
| |
| Demographic Variables | |
|
| |
| Age (years), median (IQR) |
41.0 (36.0,46.8) |
| Male, n (%) | 489 (77%) |
|
| |
| Race/Ethnicity, n (%) | |
| White | 227 (36%) |
| Black | 189 (30%) |
| Hispanic | 193 (30%) |
| Other |
27 (4%) |
| HIV-related variables | |
|
| |
| History of d-drug use, n (%) |
413 (65%) |
| Current d-drug use, n (%) | 230 (36%) |
|
| |
| Median HIV duration (years), median (IQR) |
10 (5, 15) |
| Laboratory parameters | |
|
| |
| CD4+ count (cells/mm3), median (IQR) |
131 (39, 283) |
| HIV plasma RNA (log10(copies/ml)), median (IQR) | 3.3 (2.6, 4.7) |
|
| |
| Hemoglobin (g/dL), median (IQR) |
13.3 (12.0, 14.5) |
| Glucose mg/dL, median (IQR) | 89 (76, 102) |
|
| |
| Substance use variables | |
|
| |
| Any criteria for substance usea, n (%) | 489 (77%) |
|
| |
| Reported intravenous drug use as a risk factor for HIV-infection, n (%) |
162 (25%) |
| Urine toxicology positive, n (%) | 194 (31%) |
|
| |
| DSM-IV diagnosis of past or current substance abuse or dependence of any substance, n (%) |
427 (67%) |
| Individual substances usedb, n (%) | |
|
| |
| Alcohol |
291 (46%) |
| Cocaine | 292 (46%) |
|
| |
| Cannabis |
265 (42%) |
| Opiates | 117 (18%) |
|
| |
| Stimulants |
150 (24%) |
| Hallucinogens | 40 (6%) |
|
| |
| Sedatives |
82 (15%) |
| Other | 29 (5%) |
|
| |
| Severity of use (for any substance) |
|
| Abuse diagnosis or urine toxicology positive | 95 (15%) |
|
| |
| Dependence diagnosis |
370 (58%) |
| Number of substancesb, n (%) | |
|
| |
| 0 | 154 (24%) |
|
| |
| 1 | 124 (20%) |
|
| |
| 2–3 | 226 (36%) |
|
| |
| 4 or more | 115 (18%) |
a
Includes a DSM-IV diagnosis, self-report of intravenous drug use, or positive urine toxicology.
b
Defined as a DSM-IV diagnosis or urine toxicology positive for an individual substance.